Trigeminal Dynorphin In Comorbid Temporomandibular Disorders And Migraine-Like Pain

Sufang Liu,Hui Shu,Joshua Crawford,Feng Tao
DOI: https://doi.org/10.1016/j.jpain.2023.02.130
2023-04-01
Abstract:Migraine headache is commonly reported in patients with temporomandibular disorders (TMDs); however, the underlying mechanism is still unclear. In the present study, our aim is to investigate whether and how dynorphin in the trigeminal nociceptive system is involved in the comorbid condition. Here we used a mouse model developed previously to study this comorbidity, in which masseter muscle tendon ligation (MMTL) was performed to induce a myogenic TMD and the pre-existing TMD enabled a subthreshold dose of nitroglycerin (NTG) to produce migraine-like pain in mice. RNA sequencing followed by real-time quantitative PCR confirmation showed that MMTL plus NTG treatment increased prodynorphin (Pdyn) mRNA expression in the spinal trigeminal nucleus caudalis (Sp5C) of female, but not male, mice. Chemogenetic inhibition of Pdyn-expressing neurons or microinjection of anti-dynorphin antiserum in the Sp5C alleviated MMTL-induced masseter hypersensitivity and diminished the MMTL-enabled migraine-like pain in female mice, but not in male mice. Moreover, chemogenetic activation of Pdyn-expressing neurons or microinjection of dynA(1-17) peptide in the Sp5C enabled a subthreshold dose of NTG to induce migraine-like pain in female mice only. Taken together, our results suggest that trigeminal dynorphin plays a female-specific role in the comorbid TMDs and migraine-like pain.
neurosciences,clinical neurology
What problem does this paper attempt to address?